Efficacy of gabapentin and pregabalin for the treatment of neurogenic claudication in lumbar spinal stenosis: a double-blind randomized placebo-controlled trial
Asian Spine Journal · 31.12.2025 · 19 (6) · 916-927
DOI: 10.31616/asj.2025.0096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Spine Journal, erschienen am 31.12.2025. Verfasst von Chatupon Chotigavanichaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Faculty of Medicine Siriraj Hospital, Mahidol University.
Abstract (Originalsprache)
Study Design: A double-blind randomized placebo-controlled trial.
Purpose
To evaluate the efficacy and safety of gabapentin (GBA) and pregabalin (PGB) versus placebo in managing neurogenic intermittent claudication (NIC), functional outcomes, and quality of life in patients with lumbar spinal stenosis (LSS). Overview of Literature: GBA and PGB are frequently prescribed for NIC associated with LSS. However, evidence supporting their efficacy, either in comparison with placebo or in direct comparison between the two gabapentinoids in LSS, remains limited.
Methods
LSS patients with predominant NIC symptoms for ≥3 months were randomized (1:1:1) to receive GBA (1,800 mg/day), PGB (300 mg/day), or placebo in addition to standard conservative management, including physical therapy and naproxen. GBA and PGB were both titrated to the effective dose over 14 days. The primary outcome was NIC pain measured by Visual Analog Scale (VAS). Secondary outcomes included the Swiss Spinal Stenosis Score (SSS), self-paced shuttle walk test (SPSWT; time to NIC symptoms and walking distance), Euro-QoL Group’s 5-Dimension, 5-Level (EQ-5D-5L), and adverse effects. All outcomes were assessed monthly over 4 months.
Results
Ninety patients (mean age, 63.14 years; symptoms duration, 19.38 months) were included. All groups demonstrated significant improvements in VAS, SSS, SPSWT, and EQ-5D-5L at 4 months. At 1 and 2 months, PGB showed greater EQ-5D-5L improvement compared to GBA (mean differences: 0.07 [p=0.045] and 0.08 [p=0.001], respectively). No significant differences in other outcomes were observed between groups at any time point. Adverse effects, including dizziness and sedation, were more common in the GBA and PGB groups compared to placebo (p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Förderung
- Faculty of Medicine Siriraj Hospital, Mahidol University
Zitieren
APA
Chotigavanichaya, C., Mekariya, K., Santipas, B., Wilartratsami, S., Korwutthikulrangsri, E., Ruangchainikom, M., & Luksanapruksa, P. (2025). Efficacy of gabapentin and pregabalin for the treatment of neurogenic claudication in lumbar spinal stenosis: a double-blind randomized placebo-controlled trial. Asian Spine Journal, 19(6), 916-927. https://doi.org/10.31616/asj.2025.0096
Vancouver
Chotigavanichaya C, Mekariya K, Santipas B, Wilartratsami S, Korwutthikulrangsri E, Ruangchainikom M, et al. Efficacy of gabapentin and pregabalin for the treatment of neurogenic claudication in lumbar spinal stenosis: a double-blind randomized placebo-controlled trial. Asian Spine Journal. 2025;19(6):916-927. doi:10.31616/asj.2025.0096
BibTeX
@article{Chotigavanichaya2025,
author = {Chotigavanichaya, Chatupon and Mekariya, Korawish and Santipas, Borriwat and Wilartratsami, Sirichai and Korwutthikulrangsri, Ekkapoj and Ruangchainikom, Monchai and Luksanapruksa, Panya},
title = {Efficacy of gabapentin and pregabalin for the treatment of neurogenic claudication in lumbar spinal stenosis: a double-blind randomized placebo-controlled trial},
journal = {Asian Spine Journal},
year = {2025},
volume = {19},
number = {6},
pages = {916--927},
doi = {10.31616/asj.2025.0096}
}
EUVIMED